X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1033) 1033
humans (840) 840
animals (481) 481
female (426) 426
male (379) 379
tubulin modulators - administration & dosage (344) 344
tubulin modulators - pharmacology (328) 328
oncology (267) 267
tubulin modulators - therapeutic use (259) 259
mice (218) 218
cancer (212) 212
treatment outcome (200) 200
tubulin (197) 197
pharmacology & pharmacy (195) 195
middle aged (190) 190
cell line, tumor (189) 189
aged (173) 173
paclitaxel - administration & dosage (173) 173
paclitaxel (172) 172
antineoplastic agents - pharmacology (164) 164
tubulin - metabolism (160) 160
microtubules - drug effects (154) 154
tubulins (149) 149
cardiac & cardiovascular systems (138) 138
chemotherapy (136) 136
colchicine (134) 134
apoptosis (127) 127
analysis (124) 124
microtubules - metabolism (123) 123
rats (119) 119
research (119) 119
cell proliferation - drug effects (118) 118
antineoplastic agents - therapeutic use (109) 109
neoplasms - drug therapy (107) 107
apoptosis - drug effects (105) 105
article (105) 105
tubulin modulators - chemistry (105) 105
adult (102) 102
antineoplastic agents (102) 102
drug-eluting stents (100) 100
microtubules (100) 100
dose-response relationship, drug (99) 99
tubulin modulators - adverse effects (96) 96
antimitotic agents (95) 95
care and treatment (93) 93
cell biology (93) 93
breast neoplasms - drug therapy (91) 91
biochemistry & molecular biology (88) 88
polymerization (87) 87
neurosciences (86) 86
abridged index medicus (84) 84
medicine & public health (84) 84
tubulin modulators - pharmacokinetics (84) 84
drug therapy (82) 82
sirolimus - administration & dosage (82) 82
stents (82) 82
in-vitro (81) 81
time factors (81) 81
proteins (78) 78
antineoplastic agents - chemistry (74) 74
tumors (73) 73
chemistry, medicinal (72) 72
health aspects (71) 71
pharmacology/toxicology (70) 70
antineoplastic agents - administration & dosage (68) 68
breast cancer (68) 68
cells, cultured (66) 66
drug resistance, neoplasm (65) 65
paclitaxel - pharmacology (65) 65
xenograft model antitumor assays (64) 64
cells (62) 62
restenosis (62) 62
dosage and administration (61) 61
drugs (61) 61
physiological aspects (61) 61
research article (61) 61
structure-activity relationship (61) 61
pharmacology (60) 60
rats, sprague-dawley (60) 60
epothilones - therapeutic use (59) 59
clinical trials (57) 57
studies (57) 57
drug resistance (56) 56
colchicine - therapeutic use (55) 55
antineoplastic combined chemotherapy protocols - therapeutic use (54) 54
cancer therapies (54) 54
cell cycle - drug effects (54) 54
colchicine - pharmacology (54) 54
follow-up studies (54) 54
implantation (54) 54
stent (54) 54
antineoplastic agents - adverse effects (52) 52
cell cycle (52) 52
disease models, animal (52) 52
expression (52) 52
gene expression (52) 52
ixabepilone (52) 52
medicine (51) 51
angioplasty (50) 50
drug administration schedule (50) 50
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2013, Volume 61, Issue 4, pp. 404 - 410
Objectives The objective of this study was to determine whether colchicine 0.5 mg/day can reduce the risk of cardiovascular events in patients with clinically... 
Cardiovascular | Internal Medicine | colchicine | secondary prevention | stable coronary disease | CARDIAC & CARDIOVASCULAR SYSTEMS | FAMILIAL MEDITERRANEAN FEVER | MYOCARDIAL-INFARCTION | CORONARY | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Out-of-Hospital Cardiac Arrest - epidemiology | Intestinal Diseases - chemically induced | Humans | Out-of-Hospital Cardiac Arrest - etiology | Colchicine - administration & dosage | Coronary Disease - physiopathology | Male | Withholding Treatment - statistics & numerical data | Colchicine - adverse effects | Secondary Prevention - methods | Incidence | Brain Infarction - prevention & control | Canada - epidemiology | Coronary Disease - complications | Endpoint Determination | Tubulin Modulators - administration & dosage | Female | Drug Therapy, Combination | Tubulin Modulators - adverse effects | Acute Coronary Syndrome - epidemiology | Risk Assessment | Proportional Hazards Models | Treatment Outcome | Plaque, Atherosclerotic - etiology | Plaque, Atherosclerotic - physiopathology | Brain Infarction - etiology | Out-of-Hospital Cardiac Arrest - prevention & control | Brain Infarction - epidemiology | Acute Coronary Syndrome - etiology | Coronary Disease - drug therapy | Aged | Plaque, Atherosclerotic - drug therapy | Acute Coronary Syndrome - prevention & control | Dosage and administration | Colchicine | Cardiovascular diseases | Cardiology | Heart attack | Coronary heart disease | Heart attacks | Heart surgery | Medical services | Prevention | Confidence intervals | Motivation | Ischemia | Consent | Intestine | Atherosclerosis | Drug dosages | Plaques | Statins | Aspirin | Stroke | Stability | Health risks | Risk reduction | Leukocytes (neutrophilic) | Patients | Disease prevention | Intolerance | Arteriosclerosis | Clopidogrel | Acute coronary syndromes | Index Medicus | Abridged Index Medicus
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 3/2015, Volume 32, Issue 3, pp. 910 - 928
To formulate dendrimer-stabilized smart-nanoparticle (DSSN; pD-ANP-f) for the targeted delivery of the highly hydrophobic anticancer drug, Paclitaxel... 
Biochemistry, general | Biomedical Engineering | Biomedicine | cancer cell uptake | Pharmacy | fluorescence imaging | albumin | dendrimer | caspase activity | Medical Law | Pharmacology/Toxicology | APOPTOSIS | DRUG-DELIVERY | POLY(AMIDOAMINE) DENDRIMER | CANCER | CHEMISTRY, MULTIDISCIPLINARY | PACLITAXEL | RESISTANCE | CONJUGATE | PHARMACOLOGY & PHARMACY | TUBULIN | FOLATE | Hemolysis - drug effects | Neoplasms - metabolism | Paclitaxel - metabolism | Paclitaxel - pharmacology | Apoptosis - drug effects | Tubulin Modulators - pharmacology | Humans | Drug Carriers | Dose-Response Relationship, Drug | Nanoparticles | Paclitaxel - chemistry | Antineoplastic Agents, Phytogenic - administration & dosage | Microtubules - metabolism | Paclitaxel - toxicity | MCF-7 Cells | Microtubules - drug effects | Surface Properties | Inhibitory Concentration 50 | Tubulin Modulators - administration & dosage | Tubulin Modulators - metabolism | Antineoplastic Agents, Phytogenic - metabolism | Paclitaxel - administration & dosage | Tubulin Modulators - toxicity | Dendrimers - toxicity | Tubulin Modulators - chemistry | Jurkat Cells | Drug Stability | Solubility | Antineoplastic Agents, Phytogenic - chemistry | Technology, Pharmaceutical - methods | Microtubules - pathology | Chemistry, Pharmaceutical | Hep G2 Cells | Antineoplastic Agents, Phytogenic - toxicity | Particle Size | Dendrimers - chemistry | Hydrophobic and Hydrophilic Interactions | Cell Proliferation - drug effects | Kinetics | Antineoplastic Agents, Phytogenic - pharmacology | Neoplasms - pathology | Nanotechnology | Hydrogen-Ion Concentration | Liver cancer | Therapeutics | Fluorescence | Polymerization | Drugstores | Tubulins | Homeopathy | Materia medica and therapeutics | Pharmaceutical sciences | Cancer | Index Medicus
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 8/2011, Volume 68, Issue 2, pp. 445 - 455
The natural flavonoid fisetin was recently identified as a lead compound that stabilizes endothelial cell microtubules. In this study, we investigated the... 
Fisetin | Lewis lung carcinoma | Angiogenesis | Antitumour activity | Cyclophosphamide | Medicine & Public Health | Cancer Research | Oncology | Cytotoxicity | EA·hy 926 endothelial cells | Pharmacology/Toxicology | Flavonoid | EA•hy 926 endothelial cells | APOPTOSIS | ANTIINFLAMMATORY ACTIVITY | ACTIVATION | CELL-CYCLE ARREST | PROLIFERATION | METASTATIC COLORECTAL-CANCER | IN-VITRO | ONCOLOGY | ENDOTHELIAL-CELLS | PHARMACOLOGY & PHARMACY | EA.hy 926 endothelial cells | INHIBITORS | NIH 3T3 Cells | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Tubulin Modulators - pharmacology | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents, Alkylating - pharmacology | Flavonoids - adverse effects | Antineoplastic Agents, Alkylating - administration & dosage | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Flavonoids - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Angiogenesis Inhibitors - administration & dosage | Antineoplastic Agents, Phytogenic - administration & dosage | Angiogenesis Inhibitors - therapeutic use | Flavonoids - administration & dosage | Tubulin Modulators - administration & dosage | Female | Flavonoids - pharmacology | Antineoplastic Agents, Phytogenic - therapeutic use | Angiogenesis Inhibitors - adverse effects | Antineoplastic Agents, Phytogenic - adverse effects | Cell Line | Cell Survival - drug effects | Tubulin Modulators - adverse effects | Mice, Inbred C57BL | Angiogenesis Inhibitors - pharmacology | Tubulin Modulators - therapeutic use | Carcinoma, Lewis Lung - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Cell Movement - drug effects | Animals | Tumor Burden - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Endothelial Cells - cytology | Neovascularization, Pathologic - drug therapy | Cyclophosphamide - pharmacology | Carcinoma, Lewis Lung - pathology | Cell Proliferation - drug effects | Mice | Antineoplastic Agents, Alkylating - adverse effects | Antineoplastic Agents, Phytogenic - pharmacology | Cell Cycle - drug effects | Endothelial Cells - drug effects | Antimitotic agents | Flavonoids | Flavones | Lung cancer | Bioflavonoids | Accountants | Drug therapy, Combination | Universities and colleges | Antineoplastic agents | Endothelium | Tumors | Index Medicus | cytology | Antineoplastic Agents, Phytogenic | pathology | Cell Proliferation | Endothelial Cells | Tubulin Modulators | Neovascularization, Pathologic | fisetin | administration & dosage | pharmacology | flavonoid | Carcinoma, Lewis Lung | Antineoplastic Agents, Alkylating | cytotoxicity | drug therapy | Cell Survival | angiogenesis | Antineoplastic Combined Chemotherapy Protocols | drug effects | Tumor Burden | Angiogenesis Inhibitors | EA.hy 926 | Cell Cycle | antitumour activity | adverse effects | therapeutic use | Cell Movement
Journal Article
Journal Article
Journal Article
CIRCULATION, ISSN 0009-7322, 03/2012, Volume 125, Issue 9, pp. 1110 - U108
Journal Article
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 10/2015, Volume 76, Issue 4, pp. 699 - 712
nab-paclitaxel demonstrates improved clinical efficacy compared with conventional Cremophor EL (CrEL)-paclitaxel in multiple tumor types. This study explored... 
Cremophor EL | Medicine & Public Health | Nanoparticle | Albumin | Oncology | Cancer Research | Taxane | Pharmacology/Toxicology | nab -paclitaxel | nab-paclitaxel | COLONY-STIMULATING FACTOR | SOLID TUMORS | PANCREATIC-CANCER | NONLINEAR PHARMACOKINETICS | PHASE-III TRIAL | BREAST-CANCER | ONCOLOGY | ENDOTHELIAL-CELLS | IN-VIVO | PHARMACOLOGY & PHARMACY | SOLVENT-BASED PACLITAXEL | CREMOPHOR EL MICELLES | Endothelium, Vascular - cytology | Paclitaxel - metabolism | Pancreatic Neoplasms - metabolism | Human Umbilical Vein Endothelial Cells - metabolism | Nanoparticles - chemistry | Humans | Capillary Permeability - drug effects | Endothelium, Vascular - drug effects | Paclitaxel - pharmacokinetics | Endosomes - metabolism | Serum Albumin, Human | Drug Delivery Systems | Pancreatic Neoplasms - drug therapy | Tissue Distribution | Antineoplastic Agents, Phytogenic - administration & dosage | Human Umbilical Vein Endothelial Cells - cytology | Endosomes - drug effects | Tubulin Modulators - administration & dosage | Tubulin Modulators - metabolism | Antineoplastic Agents, Phytogenic - metabolism | Biological Transport - drug effects | Antineoplastic Agents, Phytogenic - therapeutic use | Carcinoma - pathology | Paclitaxel - administration & dosage | Serum Albumin - chemistry | Antineoplastic Agents, Phytogenic - pharmacokinetics | Carcinoma - drug therapy | Human Umbilical Vein Endothelial Cells - drug effects | Microinjections | Tubulin Modulators - pharmacokinetics | Pancreatic Neoplasms - pathology | Cells, Cultured | Endosomes - pathology | Paclitaxel - therapeutic use | Tubulin Modulators - therapeutic use | Xenograft Model Antitumor Assays | Animals | Endothelium, Vascular - metabolism | Mice, Nude | Cell Line, Tumor | Endothelium, Vascular - pathology | Carcinoma - metabolism | Infusions, Intravenous | Serum Albumin - metabolism | Antimitotic agents | Dimethyl sulfoxide | Exhibitions | Permeability | Antineoplastic agents | Tumors | Index Medicus | Original
Journal Article
Circulation, ISSN 0009-7322, 06/2009, Volume 119, Issue 23, pp. 2986 - 2994
Journal Article
Journal Article